Author: Kathryn Atkins

Figure 1: Mechanisms involved in regulation of tumor progression by neutrophil PAD4.

Neutrophil PAD4: How Does it Function in Cancer Beyond Promoting NETosis?

October 30, 2023

“This will open a novel therapeutic approach for targeting PMN-MDSC in cancer.” BUFFALO, NY- October 30, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on March… read more

Figure 4: Loss of p53 predisposes to mammary tumors in mice and in women, but penetrance varies among individuals.

Oncotarget

Genetic Modifiers of p53 and Their Potential in Breast Cancer Therapies

October 25, 2023

“[...] p53 acts in concert with other genes that alter the penetrance of tumor phenotypes and the modifiers differ among tissues.” BUFFALO, NY- October 25, 2023 – A new editorial… read more

Figure 3: (A) Simulations of the reaction-diffusion model (solid lines) and measured follicle length (solid circles). (B) The function a(x) describing the pro-survival factor released by the regenerative stem cell pool. The inset shows a schematic of a hair follicle regressing slower as it gets shorter and closer to higher values of the pro-survival factor modeled with the function a(x) and released by the regenerative stem cells.

Oncotarget

Apoptotic Cells May Drive Cell Death in Hair Follicles During Regression Cycle

October 23, 2023

“Revealing the stem cell niche self-renewal dynamics is important not only for understanding tissue homeostasis but also for understanding the initiation of cancer [7].” BUFFALO, NY- October 23, 2023 –… read more

Figure 1: Ferroptosis regulation of GLS2 is a potential therapeutic strategy against liver diseases.

Oncotarget

GLS2 Shapes Ferroptosis in Hepatocellular Carcinoma

October 19, 2023

“[...] we hope that our findings will inform future decisions regarding treatment of liver disease.” BUFFALO, NY- October 19, 2023 – A new editorial paper was published in Oncotarget's Volume… read more

Figure 1: Working model for TME-mediated nuclear softening via LINC and emerin.

Oncotarget

The Nuclear Envelope and Breast Cancer Metastasis

October 18, 2023

“[...] ascertaining the mechanisms that enable metastatic spread can be transformational in our understanding of tumor progression and for future development of therapeutic interventions.” BUFFALO, NY- October 18, 2023 –… read more

Oncotarget

GBP3-STING Interaction in Glioblastoma Coordinates Poor Response to Temozolomide

October 17, 2023

“The paper revealed a critical role of GBP3 involving multiple [temozolomide] resistance mechanisms.” BUFFALO, NY- October 17, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on… read more

Oncotarget

Suppression of Cancer Stemness and Drug Resistance via BRAF/EGFR/MEK Inhibition in Colorectal Cancer Cells

October 11, 2023

“[...] our approach enables mechanistic studies of drug resistance with 3D cultures of primary cancer cells to develop and test treatments that suppress cancer [...].” BUFFALO, NY- October 11, 2023… read more

Figure 1: (A) Canonical STAT3 activation pathway. (B) WP1066 and TTI-101, examples of small molecule STAT3 inhibitors that are cell penetrant.

Oncotarget

STAT3 as a Target in H3K27M-mutant DMGs

October 9, 2023

“Children diagnosed with these tumors have [...] a median survival of approximately 12 months.” BUFFALO, NY- October 9, 2023 – A new editorial perspective was published in Oncotarget's Volume 14… read more

Figure 2: UGDH’s roles in cancer biology.

Oncotarget

UGDH in Clinical Oncology and Cancer Biology

October 4, 2023

“Given the potential challenges of directly inhibiting UGDH, therapeutic strategies may extend to targeting downstream pathways and upstream substrates.” BUFFALO, NY- October 4, 2023 – A new review paper was… read more

Oncotarget

An Ancient Anti-cancer Mechanism: DISE

October 3, 2023

“DISE is effective against all cancers we tested.” BUFFALO, NY- October 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 25, 2023, entitled, “DISE,… read more